EUCTR2012-003066-40-IT进行中（未招募）1 期
A Phase III, multi-center, open-label, randomized, controlled study of the efficacy and safety of oral LDE225 versus temozolomide in patients with Hh-pathway activated relapsed medulloblastoma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 109
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients aged >= 4 months - Patients with histologically confirmed diagnosis of MB, who have experienced relapse or progression - Only patients with a test result, using the 5-gene Hh signature assay, indicating Hh-pathway activated MB are eligible for this study. - At least one measurable lesion - Adequate renal function - Adequate liver function - Adequate bone marrow function - Serum CK <= 1.5 ULN Other protocol defined inclusion criteria may apply.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 48
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 59
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •- Systemic anticancer treatment within 2 weeks before first dose of study treatment - Focal radiation therapy within 4 weeks before first dose of study treatment, or full spinal radiotherapy within 3 months before first dose of study treatment. - Patients who have neuromuscular disorders that are associated with elevated CK - Any concurrent severe and/or uncontrolled medical conditions that in the investigator's opinion could put the patient at greater risk for treatment-related toxicities or confound the interpretation of clinical outcomes. - Impaired cardiac function - Clinically significant heart disease - Known diagnosis of human immunodeficiency virus (HIV), Hepatitis B or C - Impairment of GI function or GI disease - Major surgery, serious illness, or traumatic injury within 2 weeks of first dose of study treatment. - Unresolved toxicity greater than CTCAE grade 1 from previous anticancer therapy - Patients anticipated to require major surgery within the first 8 weeks of treatment - Patients who require a nasogastric tube for drug administration - Patients on concomitant treatment with drugs that are recognized to cause rhabdomyolysis - Patients receiving treatment with medications that are known to be strong inhibitors or inducers of CYP3A4/5 or are metabolized by CYP2B6 and CYP2C9. - Patients receiving unstable or increasing doses of corticosteroids - Patients receiving treatment with any enzyme-inducing anticonvulsant that cannot be discontinued at least 2 weeks before first dose of study treatment, and for the duration of the study - Investigational agents within 4 weeks or = 5 x t1/2 (whichever is longer) before first dose of study treatment. - Pregnant females. - Patients who are not willing to apply highly effective contraception. - Patients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment. Other protocol defined exclusion criteria may apply.
研究者
相似试验
进行中（未招募）
1 期
A clinical study to test the efficacy and safety of LDE225 compared to temozolomide in patients with a specific type of brain tumourEUCTR2012-003066-40-GBovartis Pharma Services AG22
进行中（未招募）
1 期
A clinical study to test the efficacy and safety of LDE225 compared to temozolomide in patients with a specific type of brain tumourEUCTR2012-003066-40-ESovartis Farmacéutica S.A.109
进行中（未招募）
1 期
A clinical study to test the efficacy and safety of LDE225 compared to temozolomide in patients with a specific type of brain tumourEUCTR2012-003066-40-FRovartis Pharma Services AG109
进行中（未招募）
不适用
A clinical study to test the efficacy and safety of LDE225 compared to temozolomide in patients with a specific type of brain tumourRelapsed medulloblastoma characterised by Hedgehog (Hh)-pathway activationMedDRA version: 16.1Level: PTClassification code 10066594Term: Medulloblastoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003066-40-HUovartis Pharma Services AG109
进行中（未招募）
1 期
A clinical trial to look into safety and efficacy of Abraxane as maintenancetreatment after initial treatment with Abraxane and carboplatin in patientswith a type of lung cancer named squamous cell non-small cell lung cancerSquamous Cell Non-small cell lung cancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003804-66-ITCELGENE CORPORATIO427